Information Provided By:
Fly News Breaks for March 20, 2017
STML
Mar 20, 2017 | 07:30 EDT
Ladenburg Thalmann analyst Matt Kaplan recommends using Friday's weakness in shares of Stemline Therapeutics as a buying opportunity. Following the disclosure of a death, the analyst tells investors that Stemline's patients are complicated with systemic disease impacting multiple organs. It is not uncommon to observe increased rates of cardiovascular issues including pericardial effusion and stroke in these patients, Kaplan tells investors in a research note. The data continue to "strongly support" the approval of SL-401 if the efficacy for the new cohort of patients is consistent with the prior data, the analyst contends. He reiterates a Buy rating on Stemline with a $41 price target.
News For STML From the Last 2 Days
STML
Mar 23, 2017 | 07:02 EDT
Stemline Therapeutics announced that enrollment of Stage 3 in the SL-401 pivotal trial in blastic plasmacytoid dendritic cell neoplasm, or BPDCN, has been completed. The company also reviewed key milestones for the SL-401 program over the coming year. Stemline has completed enrollment of the Stage 3 cohort of the SL-401 pivotal trial in BPDCN. Stage 3 enrolled 13 first-line BPDCN patients; statistical analysis will be based on evaluable first-line patients. The registration pathway was previously agreed upon with the FDA. Depending on the data from the trial, Stemline plans to use the results generated to support the potential filing of a Biologics License Application, or BLA, for full approval in first-line BPDCN, and is targeting possible BLA filing in the second half of this year.
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.